10.6084/M9.FIGSHARE.12992107.V1
Roman Taday
Marianne Grüneberg
Ingrid DuChesne
Janine Reunert
Thorsten Marquardt
0000-0002-9982-2981
Additional file 1 of Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)
Additional file 1: Figure S1. Layout showing the metabolic fate of mannose in mammalian cells. PMM2 is an essential enzyme catalyzing the conversion of mannose-6-phosphate to mannose-1- phosphate, which is the first step in the synthesis. Figure S2. Example of two patients, who did not stop the mannose supplementation and were still treated with mannose at the time the data was collected. Sialo-transferrin values quantified by HPLC during mannose supplementation. Figure S3. Mean blood mannose concentration obtained after every half hour from 30-300min after mannose ingestion of 1g/kg BW on clinical consultations. Figure S4. Boxplots comparing the initial tetrasialo-transferrin values before mannose therapy in responders and in non-responders. Table S1. Patients with mannose therapy reported in this study. Table S2. Clinical findings in all patients and by group (responders vs. non-responders).
Biochemistry
Space Science
Cell Biology
Biotechnology
111714 Mental Health
110309 Infectious Diseases
figshare
2020
2020-09-23
2020-09-23
Journal contribution
1125862 Bytes
10.1186/s13023-020-01528-z
10.6084/m9.figshare.12992107
CC BY + CC0